Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Crizotinib

FDA-approved product (capsule, oral), marketed as Xalkori.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Crizotinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anaplastic lymphoma kinase (alk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Crizotinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Crizotinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Phase 1 Absolute Bioavailability Study For Oral Crizotinib In Healthy Volunteers

    NCT01168934 · start 2010-08

    Registered record
    Registry ID
    NCT01168934
    Conditions
    Healthy
    Interventions
    crizotinib; crizotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-08
    Completion
    2010-09
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventioncrizotinib; crizotinib
    PhasePhase 1
    Registry statusCompleted

  • A Study To Investigate The Taste Of Crizotinib Liquid In Trained Healthy Adult Volunteers

    NCT01125904 · start 2010-06

    Registered record
    Registry ID
    NCT01125904
    Conditions
    Healthy
    Interventions
    crizotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-06
    Completion
    2010-06
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventioncrizotinib
    PhasePhase 1
    Registry statusCompleted

  • An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

    NCT00932451 · start 2010-01

    Registered record
    Registry ID
    NCT00932451
    Conditions
    Carcinoma, Non-Small-Cell Lung
    Interventions
    PF-02341066
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-01
    Completion
    2015-12
    Enrolment
    1,069

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung
    InterventionPF-02341066
    PhasePhase 2
    Registry statusCompleted

  • Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer

    NCT00965731 · start 2010-01

    Registered record
    Registry ID
    NCT00965731
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    Erlotinib; Erlotinib; PF-02341066
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-01
    Completion
    2014-01
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionErlotinib; Erlotinib; PF-02341066
    PhasePhase 1
    Registry statusCompleted

  • Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

    NCT00939770 · start 2009-09-21

    Registered record
    Registry ID
    NCT00939770
    Conditions
    Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Refractory Anaplastic Large Cell Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma
    Interventions
    Crizotinib; Laboratory Biomarker Analysis; Pharmacological Study; Questionnaire Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2009-09-21
    Completion
    2018-12-31
    Enrolment
    122

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Refractory Anaplastic Large Cell Lymphoma +2 more
    InterventionCrizotinib; Laboratory Biomarker Analysis; Pharmacological Study; Questionnaire Administration
    PhasePhase 1 / Phase 2
    Registry statusCompleted